Quarterly report pursuant to Section 13 or 15(d)

RELATED PARTY TRANSACTIONS (Details Narrative)

v3.23.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2020
Related Party Transaction [Line Items]            
Research and development related expenses $ 448,256 $ 204,216 $ 654,795 $ 459,053    
Compensation expense         $ 30,000  
Accrued director fees 157,622   157,622   101,991  
Audit Committee [Member]            
Related Party Transaction [Line Items]            
Annual fees     7,500   20,000  
Compensation Committee [Member]            
Related Party Transaction [Line Items]            
Annual fees     5,000   15,000  
Nominating And Governance Committee [Member]            
Related Party Transaction [Line Items]            
Annual fees     3,500      
IGL Pharma Inc [Member]            
Related Party Transaction [Line Items]            
Research and development related expenses 0 $ 9,355        
IGL Pharma Inc [Member] | Service [Member]            
Related Party Transaction [Line Items]            
Due to related party 11,658   11,658   13,900  
Officers and Directors [Member]            
Related Party Transaction [Line Items]            
Proceeds from short-term notes payable           $ 45,500
Bearing interest           10.00%
Short-term notes payable outstanding $ 7,500   $ 7,500   7,500  
Nominating And Governance Committee [Member]            
Related Party Transaction [Line Items]            
Annual fees         $ 10,000  
IGL Pharma Inc [Member] | President [Member]            
Related Party Transaction [Line Items]            
Non-controlling equity interest 1.00%   1.00%      
Annual fees     $ 500